Lyell Immunopharma Financials
| LYEL Stock | USD 0.58 0.05 9.43% |
Lyell |
Lyell Immunopharma Stock Summary
Lyell Immunopharma competes with Cullinan Oncology, Monte Rosa, Revolution Medicines, Nkarta, and Generation Bio. Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US55083R1041 |
| CUSIP | 55083R104 |
| Location | California; U.S.A |
| Business Address | 201 Haskins Way, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.lyell.com |
| Phone | (650) 695 0677 |
| Currency | USD - US Dollar |
Lyell Immunopharma Key Financial Ratios
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.22 | ||||
| Target Price | 0.8 | ||||
| Number Of Employees | 300 | ||||
| Beta | -0.42 |
Lyell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lyell Immunopharma's current stock value. Our valuation model uses many indicators to compare Lyell Immunopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lyell Immunopharma competition to find correlations between indicators driving Lyell Immunopharma's intrinsic value. More Info.Lyell Immunopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Lyell Immunopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lyell Immunopharma Systematic Risk
Lyell Immunopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lyell Immunopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Lyell Immunopharma correlated with the market. If Beta is less than 0 Lyell Immunopharma generally moves in the opposite direction as compared to the market. If Lyell Immunopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lyell Immunopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lyell Immunopharma is generally in the same direction as the market. If Beta > 1 Lyell Immunopharma moves generally in the same direction as, but more than the movement of the benchmark.
Lyell Immunopharma March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lyell Immunopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lyell Immunopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lyell Immunopharma based on widely used predictive technical indicators. In general, we focus on analyzing Lyell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lyell Immunopharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.39 | |||
| Information Ratio | 0.0165 | |||
| Maximum Drawdown | 29.45 | |||
| Value At Risk | (8.11) | |||
| Potential Upside | 7.41 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.